These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 6687313)

  • 1. [Ovarian carcinoma: surgery and polychemotherapy with cisplatin. Considerations on a clinical case].
    Moresco L; Quidaciolu F; Ingravaglieri E; Sorice G
    Chir Ital; 1983 Feb; 35(1):71-6. PubMed ID: 6687313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Advanced epithelial cancers of the ovary: results of 4 chemotherapy protocols (110 cases)].
    Israël L; Lepage E; Breau JL; Aguilera J
    Bull Cancer; 1982; 69(5):426-33. PubMed ID: 6891902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination v. sequential therapy with melphalan, 5-fluorouracil and methotrexate for advanced ovarian cancer.
    Miller AB; Klaassen DJ; Boyes DA; Dodds DJ; Gerulath A; Kirk ME; Levitt M; Pearson JG; Wall C
    Can Med Assoc J; 1980 Sep; 123(5):365-71. PubMed ID: 7020903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of long-term survival of 3-years 4 months after combination chemotherapy of MTX, 5-FU and low-dose CDDP (MFP) for type 4 gastric cancer with pleuritis, peritoneal dissemination and Krukenberg tumor].
    Nakayama N; Tanabe S; Koizumi W; Higuchi K; Sasaki T; Nakatani K; Shimoda T; Nishimura K; Kobayashi N; Mitomi H; Saigenji K
    Gan To Kagaku Ryoho; 2006 Nov; 33(11):1641-4. PubMed ID: 17108732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preliminary report of a clinical trial of the treatment of patients with advanced stage III and IV ovarian cancer with melphalan, 5-fluorouracil, and methotrexate in combination and sequentially: a study of the Clinical Trials Group of the National Cancer Institute of Canada.
    Klaassen DJ; Boyes DA; Gerulath A; Levitt M; Miller AB; Pearson JG
    Cancer Treat Rep; 1979 Feb; 63(2):289-95. PubMed ID: 376135
    [No Abstract]   [Full Text] [Related]  

  • 8. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
    Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
    Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical trial of cisplatin in the treatment of ovarian carcinoma].
    Yoshizawa H; Kanazawa K; Takeuchi S; Okamura Y; Goto S; Kajiwara T
    Gan To Kagaku Ryoho; 1982 May; 9(5):822-30. PubMed ID: 6764112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Surgery in the treatment concept of epithelial ovarian cancer].
    Salzer H; Genger H; Gober S; Barrada M; Vavra N; Sevelda P
    Gynakol Rundsch; 1990; 30 Suppl 1():26-9. PubMed ID: 2079293
    [No Abstract]   [Full Text] [Related]  

  • 11. A phase I trial of intravenous melphalan, paclitaxel, and cisplatin plus granulocyte-colony stimulating factor in patients with suboptimal advanced epithelial ovarian carcinoma or peritoneal carcinoma.
    Gershenson DM; Morris M; Burke TW; Levenback C; Wolf J; Lee JJ; Thall PF; Atkinson EN; Silva EG; Wharton JT
    Cancer; 1999 Dec; 86(11):2291-300. PubMed ID: 10590370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial.
    Trimbos JB; Vergote I; Bolis G; Vermorken JB; Mangioni C; Madronal C; Franchi M; Tateo S; Zanetta G; Scarfone G; Giurgea L; Timmers P; Coens C; Pecorelli S;
    J Natl Cancer Inst; 2003 Jan; 95(2):113-25. PubMed ID: 12529344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
    Greco FA; Julian CG; Richardson RL; Burnett L; Hande KR; Oldham RK
    Obstet Gynecol; 1981 Aug; 58(2):199-205. PubMed ID: 6789265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Radical peritonectomy in 37 patients with stage II and III ovarian cancer].
    Capretti PG; Zeppieri MC; Simonetti A; Rosato S; Lovotti D; Battaini A; Capretti G; Agnes Pradelli B
    Minerva Chir; 2004 Jun; 59(3):233-41. PubMed ID: 15252388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol.
    Silvestrini R; Daidone MG; Veneroni S; Benini E; Scarfone G; Zanaboni F; Villa A; Presti M; Danese S; Bolis G
    Cancer; 1998 Jan; 82(1):159-67. PubMed ID: 9428493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cytoprotective effect of Amifostine in the combined chemotherapy of advanced ovarian carcinoma].
    Nagy P; Kádasi L
    Orv Hetil; 2000 Sep; 141(37):2027-30. PubMed ID: 11037611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Sessa C; D'Incalci M; Valente I; Bolis G; Colombo N; Mangioni C
    Cancer Treat Rep; 1982 May; 66(5):1233-4. PubMed ID: 6805951
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of advanced ovarian carcinoma with a combination of hexmethylmelamine, cyclophosphamide, methotrexate, and 5-fluorourcil (hexa-CAF) in patients with and without previous treatment.
    Neijt JP; van Lindert AC; Vendrik CP; Roozendaal KJ; Struyvenberg A; Pinedo HM
    Cancer Treat Rep; 1980; 64(2-3):323-6. PubMed ID: 6773656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of cisplat based chemotherapy on advanced ovarian cancer.
    Prasad GR; Dalal AV; Tongaonkar HB; Chatterjee S; Kamat MR
    J Postgrad Med; 1995; 41(4):95-8. PubMed ID: 10707728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A randomized clinical trial of cyclophosphamide versus adriamycin, cyclophosphamide, 5-fluorouracil and methotrexate in advanced ovarian carcinoma--a preliminary report ].
    Chylak V; Ilijas M; Krusić J; Kolarić K
    Lijec Vjesn; 1982; 104(3-4):120-2. PubMed ID: 6750298
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.